Shares of Gilead Sciences, Inc. (GILD) traded nearly 3% lower in pre-market on Friday after the company reported ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

In a report released yesterday, Matthew Biegler from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares ...

Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug delivery, and novel pain ...

Gilead Sciences Inc. closed 13.61% below its 52-week high of $119.96, which the company reached on March 10th.

About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...